Biosimilars (biological drugs very similar to other existing ones) appeared on the market more than a decade ago. Although today there are around fifty already approved in Europe, referring to a dozen original biologics – and in the coming years the number is expected to increase considerably, which already anticipates the impact that they are called to play – their Employment still does not seem to have caught on among a part of the medical community and patients.